Efficacy and safety of topical 2% dorzolamide and 0.5% timolol in cases of open angle glaucoma in a tertiary care hospital of East Singhbhum: an observational, prospective and comparative study

Background: Present study was undertaken to evaluate and compare the efficacy and side effects of 2% dorzolamide and 0.5% timolol in patients with open angle glaucoma.Methods: There were 60 randomly selected patients were equally divided into Group I (n=30) and Group II (n=30). Further both groups were divided into IA (n=10), IB (n=20), IIA (n=10) and IIB (n=20). 2% Dorzolamide hydrochloride in Group IA and IIA and 0.5% Timolol maleate in Group IB and IIB was administered for 24 weeks. Patients were evaluated for general and ocular examinations on day of enrolment and then at the end of 1st, 4th, 8th and 24th week. Adverse effects of the drug during study period were also noted. Mean±SD, t value, p value and comparison between groups were analysed by graph pad software.Results: At the end of 24 weeks difference in mean reduction of IOP was not significant with 6.2±1.85mm Hg (Right eye) and 5.55±1.68mm Hg (left eye) and 4.72±2.97mm Hg (Right eye) and 5.37±1.24mm Hg (left eye) in Group IA and Group IIA respectively. At the end of 24 weeks difference in mean reduction of IOP was not significant with 5.06±1.62mm Hg (Right eye) and 4.40±1.96mm Hg (left eye) and 4.30±1.41mm Hg (Right eye) and 4.12±2.08mm Hg (left eye) in Group IB and Group IIB respectively. Fall in both systolic and diastolic blood pressure in both the groups were significant. Both drug regimens were well-tolerated, and no serious drug-related adverse effects were reported.Conclusions: Dorzolamide was more efficacious for reduction of intra ocular pressure, well-tolerated, had low allergic response and had a favourable ocular, cardiovascular and respiratory safety profile than Timolol.

A METHOD AND SYSTEM FOR PROVIDING NON-VISUAL INTERACTION BASED AUTHENTICATION

The present disclosure relates to a method and system for providing non-visual interaction based authentication. Such non-visual interaction based authentication may be provided in any user equipment of a user. Moreover, such non-visual interaction based authentication may be especially provided for specially abled users which utilise accessibility features. The method includes combining non-visual interaction modalities for entering authentication pin discreetly, using buttons or other modalities available on the user equipment

CONTINUOUS AUTHENTICATION USING ACCESSIBILITY SETTINGS AND USAGE ANALYSIS

The present invention discloses a method and system for continuous authentication using accessibility settings and usage analysis which can be used during mobile application login. An Artificial Intelligence (AI) based system, continuously captures and analyses a specially abled user’s behaviour and accessibility settings. The AI would then come up with a risk based score. This risk score will then be used to decide whether or not to skip Multi Factor Authentication (MFA)

Study of self drug administration among second professional medical students

Background: Self-medication is very common in our day to day life which is an unhealthy and risky practice. Present study was done to determine the knowledge, attitude and practice among second professional medical students.Methods: A questionnaire related to self-medication with consent was prepared and distributed among the students of second professional. Data was collected and analysed the results expressed as counts and percentages.Results: Total 100 students participated in the study for taking self-medication and was no need to visit the doctor for minor illness. In maximum students, source of information of the drugs used for self-medication pharmacological based and learning process in the college. The source of drug was medical store. Most of the students took self-medication for loose motion and headache followed by cough, cold and fever. Out of total 100 students most of the students took paracetamol tablet as self-medication.Conclusions: This study showed that second professional medical students after studying pharmacological books they do not use any wrong medicine as self-medication. High level of awareness of second professional students has minimized self medication

A METHOD AND USER EQUIPMENT FOR PROVIDING VIBRATION BASED COMMUNICATION OF SENSITIVE INFORMATION FOR VISUALLY IMPAIRED USERS

The present disclosure relates to a method and user equipment (UE) (102) for providing vibration-based communication of sensitive information for visually impaired users (101). In the present disclosure, initially the UE (102) may receive a request from the visually impaired user (101) to access information present on a virtual card. The UE (102) detects whether the information requested corresponds to be sensitive information. Further, the UE (102) encodes the information into a vibration pattern on confirming it to be sensitive information. Finally, the UE (102) generates the encoded vibration patterns for the visually impaired users (101) to complete the transaction, wherein the visually impaired user (101) refers to an instruction manual to decode the vibration pattern

Visa Accessible Card (VAC) for specially abled users

The present disclosure relates to a VISA Accessible Cards (VAC) (202) which are designed for easy and secure transactions. The VAC (202) has limited alphabetic characters (102) as the card number, presented in Braille (104) and regular characters for both specially abled people and normal people. The card may not have other details like CVV or expiry date. The card information, such as PAN, expiry date, and CVV may be mapped to the VAC characters and stored securely in a cloud server. Users may choose different engravings on front of the card for easy identification. The card may accompanied by the VAC app, which requires biometric authentication for all transactions

Precision measurements of A1N in the deep inelastic regime

We have performed precision measurements of the double-spin virtual-photon asymmetry A1A1 on the neutron in the deep inelastic scattering regime, using an open-geometry, large-acceptance spectrometer and a longitudinally and transversely polarized 3He target. Our data cover a wide kinematic range 0.277≤x≤0.5480.277≤x≤0.548 at an average Q2Q2 value of 3.078 (GeV/c)2, doubling the available high-precision neutron data in this x range. We have combined our results with world data on proton targets to make a leading-order extraction of the ratio of polarized-to-unpolarized parton distribution functions for up quarks and for down quarks in the same kinematic range. Our data are consistent with a previous observation of anA1n zero crossing near x=0.5x=0.5. We find no evidence of a transition to a positive slope in(Δd+Δd¯)/(d+d¯) up to x=0.548x=0.548

Production of He-4 and (4) in Pb-Pb collisions at root(NN)-N-S=2.76 TeV at the LHC

Results on the production of He-4 and (4) nuclei in Pb-Pb collisions at root(NN)-N-S = 2.76 TeV in the rapidity range vertical bar y vertical bar <1, using the ALICE detector, are presented in this paper. The rapidity densities corresponding to 0-10% central events are found to be dN/dy4(He) = (0.8 +/- 0.4 (stat) +/- 0.3 (syst)) x 10(-6) and dN/dy4 = (1.1 +/- 0.4 (stat) +/- 0.2 (syst)) x 10(-6), respectively. This is in agreement with the statistical thermal model expectation assuming the same chemical freeze-out temperature (T-chem = 156 MeV) as for light hadrons. The measured ratio of (4)/He-4 is 1.4 +/- 0.8 (stat) +/- 0.5 (syst). (C) 2018 Published by Elsevier B.V.Peer reviewe

Canagliflozin and renal outcomes in type 2 diabetes and nephropathy

BACKGROUND Type 2 diabetes mellitus is the leading cause of kidney failure worldwide, but few effective long-term treatments are available. In cardiovascular trials of inhibitors of sodium–glucose cotransporter 2 (SGLT2), exploratory results have suggested that such drugs may improve renal outcomes in patients with type 2 diabetes. METHODS In this double-blind, randomized trial, we assigned patients with type 2 diabetes and albuminuric chronic kidney disease to receive canagliflozin, an oral SGLT2 inhibitor, at a dose of 100 mg daily or placebo. All the patients had an estimated glomerular filtration rate (GFR) of 30 to &lt;90 ml per minute per 1.73 m2 of body-surface area and albuminuria (ratio of albumin [mg] to creatinine [g], &gt;300 to 5000) and were treated with renin–angiotensin system blockade. The primary outcome was a composite of end-stage kidney disease (dialysis, transplantation, or a sustained estimated GFR of &lt;15 ml per minute per 1.73 m2), a doubling of the serum creatinine level, or death from renal or cardiovascular causes. Prespecified secondary outcomes were tested hierarchically. RESULTS The trial was stopped early after a planned interim analysis on the recommendation of the data and safety monitoring committee. At that time, 4401 patients had undergone randomization, with a median follow-up of 2.62 years. The relative risk of the primary outcome was 30% lower in the canagliflozin group than in the placebo group, with event rates of 43.2 and 61.2 per 1000 patient-years, respectively (hazard ratio, 0.70; 95% confidence interval [CI], 0.59 to 0.82; P=0.00001). The relative risk of the renal-specific composite of end-stage kidney disease, a doubling of the creatinine level, or death from renal causes was lower by 34% (hazard ratio, 0.66; 95% CI, 0.53 to 0.81; P&lt;0.001), and the relative risk of end-stage kidney disease was lower by 32% (hazard ratio, 0.68; 95% CI, 0.54 to 0.86; P=0.002). The canagliflozin group also had a lower risk of cardiovascular death, myocardial infarction, or stroke (hazard ratio, 0.80; 95% CI, 0.67 to 0.95; P=0.01) and hospitalization for heart failure (hazard ratio, 0.61; 95% CI, 0.47 to 0.80; P&lt;0.001). There were no significant differences in rates of amputation or fracture. CONCLUSIONS In patients with type 2 diabetes and kidney disease, the risk of kidney failure and cardiovascular events was lower in the canagliflozin group than in the placebo group at a median follow-up of 2.62 years